Neurosurgery is a surgical specialty concerned with the treatment of disorders and diseases related to the spinal cord, sympathetic and peripheral nervous system, and brain. Medications related to neurosurgical conditions include four drugs: Phenytek, Phenytoin Sodium, Dilantin, and Phenytoin. These are anti-epileptic drug or anticonvulsant. Epilepsy causes recurrent seizures that are unprovoked by neurologic insults or acute systemic. Phenytoin is used to control these seizures by slowing down brain impulses caused by this disorder. Seizures can occur due to bleeding in the brain caused by injuries, brain tumors, or brain surgery. Phenytoin sodium is included under the drug class Hydantoins. Phenytoin is a hydantoin derivative anticonvulsant drug. Phenytoin sodium is used to reduce neuropathic pain, cardiac glycoside intoxication, cardiac arrhythmias, status epilepticus, seizures associated with neurosurgery, absence (petit mal) seizures, partial seizures, and tonic-clonic seizures.
Long-term side effects of cerebellar ataxia and osteopenia, reduce their use by neurologists. Neurosurgery drugs have narrow therapeutic index and zero-order kinetics that makes these drugs to be one of the most difficult antiepileptic drugs to use. Moreover, these drugs are likely to have significant bidirectional drug interactions. Some neurosurgery drugs may cause difficulty in coordinating movements, confusion, headaches, nausea, dizziness, and drowsiness. If these drugs are ingested during pregnancy, they can causing various abnormalities in the baby.
The neurosurgery drugs market is driven by the rise in geriatric population with neurological disorders. The Global Campaign against Epilepsy sponsored by the International League against Epilepsy, the International Bureau for Epilepsy, and the World Health Organization advocates using phenobarbital to increase health promotions in low-income countries. This projected to boost the neurosurgery drugs market. According to the book Neurological Disorders, written by Rajesh Pandav, Ramanan Laxminarayan, Vijay Chandra, and others, states that a study conducted in developed countries on people who underwent epilepsy surgery indicated that 58% of them are seizure free, while 10% to 15% people have less frequent seizures, and even if the patients have less or no seizures, medications need to be continued for one to two years. This is projected to support the expansion of the neurosurgery drugs market. Statistics from the World Health Organization suggests that the global burden of neurological diseases was approximately 92 million disability-adjusted life years (DALYs) in 2005 and is estimated to reach 103 million DALYs by the end of 2030. Rapidly increasing burden of neurological diseases is likely to increase the number of neurological surgeries, thereby increasing the demand for neurosurgery drugs.
The neurosurgery drugs market can be segmented based on drug class, disease type, distribution channel, and region. In terms of drug class, the market can be categorized into hydantion anticonvulsants, and group I antiarrhythmics. Based on disease type, the neurosurgery drugs market can be classified into neuropathic pain, cardiac glycoside intoxication, cardiac arrhythmias, status epilepticus, seizures associated with neurosurgery, absence (petit mal) seizures, partial seizures, and tonic-clonic seizures. In terms of the distribution channel, the market can be segmented into retail pharmacies, hospital pharmacies, and online pharmacies.
Based on geography, the neurosurgery drugs market can be divided into Latin America, Asia Pacific, Europe, North America, and Middle East & Africa. North America accounted for a large share of the market in 2016 owing to the increasing geriatric population and rise in research & development activities. Europe held the second large share of the market in 2016, due to rising stress levels and increasing inclination toward drug addiction for pain relief, which are expected to boost the demand for neurosurgery drugs. The market in Asia Pacific is anticipated to expand at a moderate pace during the forecast period owing to technological advancements and increasing stress levels in developed and developing countries. The market in Middle East & Africa and Latin America is projected to expand during the forecast period due to increasing health promotions in these countries.
Key players operating in the neurosurgery drugs market are Pfizer Inc., Sun Pharmaceutical Industries Limited, WOCKHARDT, and Mylan N.V.
This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.
Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:
- Customer Experience Maps
- Insights and Tools based on data-driven research
- Actionable Results to meet all the business priorities
- Strategic Frameworks to boost the growth journey
The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.
The following regional segments are covered comprehensively:
- North America
- Asia Pacific
- Latin America
- The Middle East and Africa
The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.
Below is a snapshot of these quadrants.
1. Customer Experience Map
The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.
2. Insights and Tools
The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.
3. Actionable Results
The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.
4. Strategic Frameworks
The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.
The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:
1. What can be the best investment choices for venturing into new product and service lines?
2. What value propositions should businesses aim at while making new research and development funding?
3. Which regulations will be most helpful for stakeholders to boost their supply chain network?
4. Which regions might see the demand maturing in certain segments in near future?
5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?
6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?
7. Which government regulations might challenge the status of key regional markets?
8. How will the emerging political and economic scenario affect opportunities in key growth areas?
9. What are some of the value-grab opportunities in various segments?
10. What will be the barrier to entry for new players in the market?
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.